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Summary A 6-month exposure of ZR-75-1 human breast cancer cells to tamoxifen (1 UM rising to 2PM),
resulted in a fall in oestrogen receptor (ER) levels from 225 fmol mgprotein-1 to 56fmolmgprotein-1 while
progesterone receptor (PGR) concentration fell from 63 fmol mgprotein-1 to undetectable levels. Sensitivity to
the anti-proliferative effects of tamoxifen was unchanged. A further 6 months' exposure to 4 MM tamoxifen
resulted in loss of detectable ER and PGR and development of resistance to tamoxifen. Resistant cells,
designated ZR-75-9al, displayed morphological changes consistent with the acquisition of a less well
differentiated phenotype. Flow cytometric studies demonstrated that the cell cycle distribution pattern of the
resistant variant growing in the presence of 8 MM tamoxifen was identical to that of the untreated parent line,
which showed marked accumulation of cells in GO/GI when exposed to 8 MM tamoxifen. The resistant
phenotype was not stable if cells were transferred to complete drug-free medium, but remained stable for at
least 3 months in the presence of medium lacking oestrogenic activity. ZR-75-9al cells differ from previously
reported tamoxifen-resistant variants of the MCF-7 line which retain ER and may prove a valuable model for
the study of the development and stability of tamoxifen resistance in human breast cancer.
The anti-oestrogen tamoxifen is of proven value in the
treatment of advanced breast cancer in post-menopausal
women with approximately 50% of oestrogen receptor (ER)
positive tumours showing a response to therapy (Mouridsen
et al., 1978). A large subset of ER-positive tumours therefore
do not respond, and patients may also relapse following an
initial response to the anti-oestrogen. Paradoxically, patients
resistant to tamoxifen may respond to alternative hormonal
therapy and among patients acquiring 'resistance' to
tamoxifen some may show a further response on subsequent
re-challenge with the drug.
The availability of a number of cell lines derived from
human breast cancer has greatly aided studies on the
mechanism of oestrogen control of breast cancer cell
proliferation and its inhibition by anti-oestrogens. The
development of anti-oestrogen resistant variants from such
lines should provide further insight into the mechanism of
action of and development of resistance to anti-oestrogens.
The majority of studies to date have shown that resistance is
not associated with the acquisition of an ER-negative
phenotype. Thus both the R3 (Nawata et al., 1981b) and
R27 (Nawata et al., 1981a) tamoxifen-resistant sub-lines
derived from MCF-7 retain ER, although they differ in a
number of responses to.oestrogen stimulation. Neither of
these lines, however, maintains the resistant phenotype in the
absence of continuing tamoxifen exposure (Bronzert et al.,
1986). LY2, an MCF-7 variant, was selected for its ability
to grow in the presence of the potent anti-oestrogen
LY 117018, and is cross-resistant to tamoxifen. This line also
expresses ER, although to a lesser extent than MCF-7, and
seems to be stably resistant to anti-oestrogens (Bronzert et
al., 1985). A tamoxifen and oestrogen insensitive variant of
the T47D line, lacking ER but expressing high levels of
progesterone receptor (PGR), has also been described but
this line arose as a result of changes in culture conditions
rather than under selective pressure of anti-oestrogen
exposure (Horwitz et al., 1982).
In this paper we describe what is, to our knowledge, the
first tamoxifen-resistant variant of the ZR-75-1 human
breast cancer cell line. This variant arose during prolonged
Correspondence: H.W. van den Berg.
Received 22 September 1988, and in revised form, 22 October 1988.
exposure of the parent line to increasing concentrations of
tamoxifen and appears to represent a novel resistant pheno-
type having lost both ER and PGR. We also describe
ultrastructural characteristics of this variant and report on
phenotypic stability in the absence of continuing selective
pressure.
Materials and methods
Cell culture and development of the ZR-75-9a1 subline
The ZR-75-1 human breast cancer cell line was obtained
from Flow Laboratories (Irvine, Scotland) and is well
characterised (Engel et al., 1978). Cells were routinely
maintained in RPMI 1640 medium supplemented with 5%
fetal calf serum, 100IUml-1 penicillin and 100 igml-l
streptomycin and grown in an air:CO2 atmosphere at 37°C.
In February 1985 a semi-confluent flask of ZR-75-1 cells
was exposed to 1 M tamoxifen and routinely subcultured in
medium containing this concentration of drug for one
month. The tamoxifen concentration was then raised to 2pM
for a further 6 months at which time the concentration was
doubled again to 4pM. During this period tamoxifen
exposed cells were subcultured once weekly at a split ratio of
1:3, whilst the parent line was subcultured twice weekly. ER
and PGR receptor expression was assessed regularly during
this period and during the following year, at which time the
electron microscopic studies were performed. ER and PGR
were determined using a whole cell binding assay as
previously described (van den Berg et al., 1987). Tamoxifen
was withdrawn from cells for three days before determining
receptor expression. In certain experiments cells were
transferred to RPMI medium devoid of the weakly
oestrogenic pH indicator phenol red (Berthois et al., 1986)
and supplemented with 5% fetal calf serum stripped of
endogenous steroids using dextran coated charcoal (FCSdcc).
The sensitivity of tamoxifen exposed cells, designated ZR-75-
9a1, to re-exposure to the drug was compared to that of the
parent line by assessing cell numbers following 6 days'
continuous treatment (van den Berg et al., 1987). Flow
cytometric studies were carried out in early 1988, at which
time ZR-75-9al cells had been routinely maintained in 8pM
tamoxifen for 4 months.
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Electron microscopy
Cells were processed for electron microscopy using a
modification of the method of Pentz et al. (1983). Briefly,
cells were grown in test chambers, TCSC-1 (Pentz et al.,
1981), and exposed to 3% gluteraldehyde in 0.1M sodium
cacodylate buffer, pH7.2-7.4. Cells were then post-fixed in
1% osmium tetroxide in 0.1 M sodium cacodylate buffer for
1 h then dehydrated through a series of ethanols (70% to
absolute) and propylene oxide before embedding in Epon
812 substitute resin. Application of this procedure resulted in
a resin-resin boundary region which represented the original
site of cell growth. Sections of silver-gold interference
colours were cut on a Reichert OMU2 ultramicrotome, lifted
on copper support grids and stained with ethanolic uranyl
acetate and Reynolds lead citrate.
Transmission electron micrographs were taken using a Joel
100 CX2 transmission electron microscope. Cells were
prepared for scanning microscopy by growing them in
multiwell dishes containing therminox plastic cover slips and
fixing at 4°C for 30min in a solution of 3% gluteraldehyde/
1% osmium tetroxide dissolved in distilled water. Cells were
then washed in distilled water dehydrated through alcohols,
critical point dried, mounted and coated with gold/
palladium. Scanning electron micrographs were taken using
a Joel 35CF scanning electron microscope.
Flow cytometry
Cells were removed from semi-confluent 75 cm2 flasks by
trypsinisation and suspended in complete growth medium.
Cells were pelleted by centrifugation and resuspended in
0.02% EDTA in phosphate-buffered saline (PBS) at a
concentration of 106ml-1. Ten minutes later cells were
centrifuged again, resuspended in the same volume of PBS
and passed through successively smaller gauge syringe
needles. Absolute ethanol was then added dropwise to a final
concentration of 70% and cells fixed for 1 h at 4°C.
Following centrifugation and washing with PBS, cells were
resuspended in a solution of RNAase (0.5mgml-1) and
propidium iodide (100ygml-1) in PBS at 4°C. Distribution
of cellular DNA content was assessed 24h later using an
Epics 541 flow cytometer (Coulter Electronics, Hialeh, FL)
equipped with a Coherent Innova 90 argon laser tuned to
488 nm at 300mV. Single parameter 256 channel integral red
fluorescence histograms were collected using a 590nm
dichroic mirror, 610nm glass long pass filter combination. A
minimum of 20,000 cells were analysed in each sample. Cell
cycle determinations were performed using the PARA1
analysis program.
Results
Six months' exposure of ZR-75-1 cells to tamoxifen (1-2uM)
resulted in a fall in ER content from 225 to
56fmolmgprotein-1 and PGR was undetectable. A further 6
months ofcontinuous exposure to 4pM tamoxifen resulted in
both ER and PGR expression falling to undetectable levels
(Table I). At this time ZR-75-9al cells were markedly
resistant to the anti-proliferative effects of tamoxifen (Figure
1) while the initial fall in ER content was not associated with
any change in tamoxifen sensitivity (data not shown). Figure
1 also shows that growth inhibition by tamoxifen (up to
2gM) is reversed in the parent line in the presence of 10-9 M
oestradiol. Interestingly, the ZR-75-9al subline also shows
resistance to a concentration of tamoxifen (4pM), the effects
of which in the parent line are not reversed by oestradiol. At
the seeding density employed in this experiment (40,000 cells
per well), the doubling time of ZR-75-9al cells in the
absence of drug (66+3h) was longer than that of the parent
line (51 +2h). If ZR-75-1 cells are transferred to medium
lacking phenol red and supplemented with a 5% FCSdcc,
there is a marked fall in proliferative rate within one week
Table I Oestrogen and progesterone receptor expression by ZR-75-1 and ZR-75-9al
cells. Values are mean and s.e. of three determinations
Bax Kd
(fmolmgprotein-1) (nM)
ZR-75-1 ER 225+19 0.57+0.11
PGR 63+18 0.21+0.06
ZR-75-9al ER 56+12 0.21+0.08
(6 months in tamoxifen) PGR Not detectable (<15 fmol mgprotein 1)
ZR-75-9al ER Not detectable (<10 fmolmgprotein-1)










Figure 1 The effect of tamoxifen alone or in the presence of 10-9M oestradiol on the proliferation of ZR-75-1 and ZR-75-9al
cells. Hatched bar, ZR-75-1; filled bar ZR-75-9a1; open bar, tamoxifen in the presence of 10-9 M oestradiol. Results are means
and s.e. of three determinations. Inset: proliferation of ZR-75-1 and ZR-75-9al over a 6 day period; the effect of E2 on oestrogen
withdrawn cells. Open bar, cells grown in 'complete' medium; hatched bar, cells grown in phenol red free medium supplemented
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Figure 2 (a) Phase contrast photomicrograph of ZR-75-1 cells,
x 75; (b) phase contrast photomicrograph of ZR-75-9al cells,
x75.
Figure 4 (a) Scanning electron micrograph of ZR-75-1 cells
showing abundant surface microvilli; (b) scanning electron micro-
graph of ZR-75-9al cells. Density of surface microvilli is much
reduced compared to the parent line.
Figure 3 (a) Transmission electron micrograph of ZR-75-1 cells.
A microvilli-lined intracellular vacuole is shown (IV) together
with large numbers of saturated lipid inclusion bodies (L).
x 1,400. (b) Transmission electron micrograph of ZR-75-9al
cells. The nuclear cytoplasmic ratio appears larger that that of
the parent line; lipid inclusion bodies are much reduced and
neither desmosomes nor tonofilaments have been observed.
x 1,400.
with the doubling time extending to approximately 160h.
Under these circumstances 10-9 M oestradiol (E2) is
markedly growth stimulatory (Figure 1 inset), as previously
reported (Glover et al., 1988). As expected, transfer of ZR-
75-9al cells to phenol red free medium had no effect on
growth rate, which was also unaffected by E2 treatment.
Under phase contrast microscopy ZR-75-9al cells
appeared smaller and more rounded than the parent line
(Figures 2a and b) and also failed to reach full confluence,
tending to grow in 'islands'. Transmission electron
microscopy of the parent line revealed many of the features
originally described (Engel et al., 1978), including large
irregular nuclei, saturated lipid inclusion bodies, tono-
filaments, desmosomes and microvilli-lined intracellular
vacuoles (Figure 3a). ZR-75-9al cells, however, contained
very little lipid, tonofilaments and desmosomes have not
been observed and the nuclear:cytoplasmic ratio appeared
larger than that of the parent line (Figure 3b). Scanning
electron miroscopy revealed a marked reduction in the
density of surface microvilli in the ZR-75-9al line compared
to ZR-75-1 (Figures 4a and b).
Table II demonstrates that a 5-day exposure of ZR-75-1
cells to 8 iM tamoxifen results in an accumulation of cells in
the GO/GI phase of the cell cycle with a corresponding fall
in the proportion of cells in S and G2/M. In contrast, ZR-
75-9al cells routinely maintained in medium containing the
same concentration of the anti-oestrogen had a virtually
identical cell cycle profile to the untreated parent line.
If ZR-75-9al cells are transferred to drug-free 'complete'
medium (containing phenol red and serum associated
oestrogen), both ER and PGR are detectable within 4 weeks
and basal PGR levels can be induced further during a 5-day
exposure to 10-9 M oestradiol (Table III). This return to
receptor positivity was associated with a return to sensitivity
to tamoxifen although the appearance of cells under phaseTAMOXIFEN-RESISTANT VARIANT OF ZR-75-1 525
Table H Cell cycle phase distribution of ZR-75-1 and ZR-75-9al
cells by flow cytometry
% Cell cycle phase
distribution
Cell line GO+GI S G2+M
ZR-75-1 53.8 22.1 24,1
ZR-75-1, 5 days
exposure to 8pM tamoxifen 78.2 9.1 6.7
ZR-75-9al, routinely
maintained in 8pM tamoxifen 54.2 21.5 24.3
Table Ill Oestrogen and progesterone receptor expression by ZR-
75-9al cells following transfer to drug-free medium. Receptor con-
centrations are expressed as fmolmgprotein-1. For induction of






free medium ER PGR ER PGR
1 n.d. n.d. n.d. n.d.
4 261 117-E2 n.d. n.d.
260+E2
6 111 189-E2 n.d. n.d.
236+E2
12 185 - n.d. n.d.
n.d., not detected.
contrast microscopy was similar to that of ZR-75-9al cells
cultured in the presence of drug. If cells are transferred from
drug-containing medium to 'oestrogen-free medium' (lacking
phenol red and supplemented with 5% FCSdcc), cells remain
ER and PGR negative and retain the tamoxifen-resistant
phenotype for at least 3 months. The appearance of these
cells under phase contrast microscopy was again in-
distinguishable from that of cells maintained in the presence
of drug.
Discussion
Our data demonstrate that prolonged culture of ZR-75-1
human breast cancer cells in the presence of increasing
concentrations of tamoxifen resulted in a gradual loss of ER
and PGR as detected using a whole cell binding assay at
37°C.
Pronounced resistance to the anti-proliferative effects
of tamoxifen was only observed when ER and PGR had
fallen to undetectable levels. The question of whether there is
a relationship between the amount of ER expression by a
tumour and the likelihood of a clinical response is a matter
of current controversy (A'Hern et al., 1985). In this respect it
is of interest that we have previously shown that interferon
alpha-induced increased ER expression in the ZR-75-1 line
correlates with increased sensitivity to tamoxifen (van den
Berg et al., 1987). Although we report a correlation betwen
loss of ER and development of anti-oestrogen resistance,
ZR-75-9al cells are also resistant to a concentration of
tamoxifen (4 uM), the effect of which in the parent line
cannot be completely reversed by oestradiol (Figure 1). The
R3 and R27 tamoxifen-resistant variants of the MCF-7 line
were also reported to be resistant to the anti-proliferative
effects of 1OpM tamoxifen (Nawata et al., 1981a,b).
Therefore the possibility that tamoxifen resistance may also
involve biochemical changes in other suggested pathways of
tamoxifen action must be considered, such as calcium
antagonism (Lipton & Morris, 1986) and inhibition of
protein kinase C (O'Brian et al., 1985).
The relationship between the morphological and ultra-
structural changes observed in the ZR-75-9al line and
tamoxifen resistance is unclear at present. The reduction in
lipid content and absence of tonofilaments and desmosomes
would be consistent with the acquisition of a less well
differentiated phenotype, as would the loss of ER. We have
previously shown that microvillogenesis in the MCF-7 cell
line is stimulated by phenol red (Nelson et al., 1987),
confirming its oestrogenic activity in this respect (Vic et al.,
1982). Our observation that prolonged exposure to anti-
oestrogens reduces microvilli density in ZR-75-1 cells would
be consistent with these earlier observations.
Our flow cytometric studies on ZR-75-1 cells (Table II)
confirm previous observations using the MCF-7 line that
tamoxifen treatment results in an accumulation of cells in
the GO/GI phase of the cell cycle (Sutherland et al., 1983).
In contrast, the cell cycle profile of ZR-75-9al cells
maintained in 8pM tamoxifen is indistinguishable from that
of the untreated parent line, despite the fact that the resistant
variant has a longer doubling time. Multiparametric flow
cytometry will be required to demonstrate possible subtle
changes in cell cycle kinetics between the two cell lines.
The ZR-75-9al resistant phenotype is not maintained if
cells are cultured in complete medium lacking tamoxifen
(Table III). This observation would argue against the pro-
position that ZR-75-9al arose as a result of selective loss of
ER-positive cells within a parent line heterogeneous with
respect to receptor content. However, these cells maintain
their altered appearance under phase contrast microscopy
in the absence of drug, suggesting that they do retain
certain aspects of an altered phenotype. ZR-75-9al cells
remain ER and PGR negative and resistant to tamoxifen if
cultured in drug-free medium devoid of oestrogenic activity.
This finding would suggest that the presence of anti-
oestrogenic activity or the absence of oestrogenic activity are
equally capable of maintaining the tamoxifen-resistant
phenotype of ZR-75-9al cells.
Both the R3 (Nawata et al., 198lb) and the R27 (Nawata
et al., 1981a) tamoxifen-resistant variants of the MCF-7 line
retain ER although PGR was not inducible in R3 by
oestradiol, indicating a defect distal to the ligand binding
step. The LY2 MCF-7 variant (Bronzert et al., 1985)
expresses a much reduced number of oestrogen binding sites,
but retains the ability to respond to oestradiol with growth
stimulation. The tamoxifen-resistant variants of MCF-7 may
be representative of the clinical situation in which an ER-
positive patient fails to respond to tamoxifen. In the case of
ZR-75-9al, a clinical parallel might be the patient who is
initially ER-positive and responds, subsequently relapsing
with an ER-negative presentation. A number of clinical
studies have demonstrated a fall in tumour ER content
during endocrine therapy, including tamoxifen treatment
(Allegra et al., 1980; Taylor et al., 1982; Nomura et al.,
1985). Conversion of an ER-positive tumour to ER
negativity as a result of tamoxifen therapy has usually been
interpreted as reflecting persistent occupation of ER by the
anti-oestrogen. This cannot explain our in vitro data since
the binding assays were carried out under exchange
conditions where ER is detectable in short-term tamoxifen-
treated cells and where reversal of tamoxifen's anti-
proliferative effects by oestradiol is achieved. Our
observation that tamoxifen resistance in ZR-75-9al cells can
be reversed may also have a clinical parallel among those
patients who initially relapse while undergoing anti-oestrogen
therapy, but respond to a later challenge with tamoxifen.
ZR-75-9al cells may be a useful model for furthering our
understanding of the development and stability of tamoxifen
resistance in human breast cancer.
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